PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

Area of Science:

• Oncology
• Immunology
• Clinical Trials

Background:

• Immune checkpoint inhibitors targeting PD-1/PD-L1 show promise in pre-treated NSCLC.
• The predictive value of PD-L1 expression remains debated.
• This analysis investigates PD-L1's role in predicting response to anti PD-1/PD-L1 therapies.

Purpose of the Study:

• To clarify the association between tumor PD-L1 expression and clinical response to anti PD-1/PD-L1 monoclonal antibodies (MoAbs).
• To evaluate PD-L1 as a predictive biomarker in pre-treated NSCLC patients.

Main Methods:

• Pooled analysis of published studies on PD-1/PD-L1 inhibitors in pre-treated NSCLC.
• Data stratified by tumor PD-L1 expression status (immunohistochemistry, ≥1% cut-off).
• Calculated Overall Response Rate (ORR) using pooled Odds Ratio (OR) and 95% Confidence Intervals (CIs).

Main Results:

• Seven studies with 914 patients were included.
• Patients with PD-L1 positive tumors (≥1% staining) had significantly higher ORR.
• Pooled OR for ORR was 2.44 (95% CIs: 1.61-3.68) favoring PD-L1 positive tumors.

Conclusions:

• PD-L1 tumor overexpression is associated with higher clinical activity of anti PD-1/PD-L1 MoAbs.
• PD-L1 expression (IHC, ≥1% cut-off) may serve as a predictive biomarker.
• Suggests potential for PD-L1 testing to guide treatment selection for NSCLC patients.